Current role
Urte Gayko
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Urte Gayko
Summit Therapeutics Inc. reported in an 8-K filed October 16, 2023 that Urte Gayko was appointed Chief Regulatory, Quality, & Pharmacovigilance Officer, effective October 16, 2023. Summit Therapeutics Inc. reported in an 8-K filed October 3, 2022 that Urte Gayko resigned as Board of the Company, effective September 28, 2022.
“Today, Summit announces that, effective immediately, the following elevated appointments have been made: Urte Gayko, PhD, as Chief Regulatory, Quality, & Pharmacovigilance Officer”
“Additionally, effective September 28, 2022, Urte Gayko resigned from the Board of the Company in order to create a vacancy for Dr. Robert Booth, PhD and to focus on her full-time role as Head of Regulatory, Safety, and Quality for the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Summit Therapeutics Inc. (SMMT)
Source not stated
Current -
2021-11-03–2022-09-28
-
2021-01-01–2022-09-28
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Summit Therapeutics Inc.
Other people whose current roles at this company are on record from its filings.
- Glyn Edwards CEO
- Mahkam Zanganeh CEO, COO, Board Member
- Robert Duggan CEO, Board Member
- Manmeet Soni CFO, Board Member
- Dr. Mahkam Zanganeh COO, Board Member
- Manmeet S. Soni COO
- Bhaskar Anand Chief Accounting Officer
- Jeffrey R. Maranian Chief Accounting Officer
- Alessandra Cesano Board Member
- Dr. Alessandra Cesano, MD, PhD Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.